| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) | Phase 2 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms | Details | |
| KRAS Neoantigen Nanovaccine (The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School) | Phase 2 Clinical | The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School | Colorectal Neoplasms; Pancreatic Neoplasms | Details | |
| HBW-012462 | HBW-012462 | Phase 2 Clinical | Hyperway Pharmaceutical Co Ltd | Solid tumours | Details |
| JAB-23E73 | JAB-23E73 | Phase 2 Clinical | Jacobio Pharmaceuticals Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| ZG-2001 | ZG2001; ZG-2001 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | Details |
| ELI-002 | ELI-002 2P; Amph-CpG-7909; ELI-002; VED-002 | Phase 2 Clinical | Elicio Therapeutics | Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Solid tumours | Details |
| mDC3/8-KRAS Vaccine (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Carcinoma, Pancreatic Ductal | Details | |
| small molecule Ras inhibitors (Boehringer Ingelheim/Vanderbilt University) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms | Details | |
| KRAS peptide vaccine (Sidney Kimmel Cancer Center/Bristol-Myers Squibb) | Phase 1 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms | Details | |
| KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms | Details | |
| HB-700 | HB700; HB-700 | Phase 1 Clinical | Hookipa Pharma Inc | Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
| KST-6051 | KST-6051 | Phase 1 Clinical | Kestrel Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | Details |
| TQB-3205 | TQB-3205; TQB3205 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Neoplasms | Details |
| PT-0511 | PT-0511; PT0511 | Phase 1 Clinical | PAQ Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| TLN-372 | TLN-372 | Phase 1 Clinical | Treeline Biosciences Inc | Solid tumours | Details |
| ASP-5834 | ASP5834; ASP-5834 | Phase 1 Clinical | Astellas Pharma Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | Details |
| AMG-410 | AMG-410; AMG 410 | Phase 1 Clinical | Amgen Inc | Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours | Details |
| MPD-1 | MPD-1 | Phase 1 Clinical | Pharosgen Co Ltd | Neoplasms; Solid tumours | Details |
| KRAS protein modulator (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| PF-07985045 | PF-07985045; PF-5045 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | Details |
| LY-4066434 | LY-4066434 | Phase 1 Clinical | Loxo Oncology Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | Details |
| BGB-53038 | BGB-53038 | Phase 1 Clinical | BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | Details |
| KRAS Neoantigen mRNA Vaccine(Abogen Biosciences) | ABO2102; ABO-2102 | Phase 1 Clinical | Abogen Biosciences Co Ltd | Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Solid tumours | Details |
| PF-07934040 | PF-4040; PF-07934040 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | Details |
| ERAS-4001 | ERAS-4001 | Phase 1 Clinical | Erasca Inc | Solid tumours | Details |
| BBO-11818 | BBO-11818 | Phase 1 Clinical | Bridgebio Pharma Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
| ALTA-3263 | ALTA-3263 | Phase 1 Clinical | Alterome Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| QTX-3544 | QTX-3544; QTX3544 | Phase 1 Clinical | Quanta Therapeutics Inc | Neoplasms; Solid tumours | Details |
| AN-9025 | AN-9025; AN9025 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Adenocarcinoma of Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| BI-3706674 | BI-3706674; BI3706674; BI 3706674 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| YL-17231 | YL-17231; YL17231; TEB-17231 | Phase 1 Clinical | YL-Pharma | Neoplasms; Solid tumours | Details |
| QTX-3034 | QTX3034; QTX-3034 | Phase 1 Clinical | Quanta Therapeutics Inc | Neoplasms; Solid tumours | Details |
| Zoldonrasib | RMC-9805; RM-036 | Phase 1 Clinical | Revolution Medicines Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| BEBT-607 | C200825009-FP; BEBT-607 | Phase 1 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| BI-1701963 | BI-1701963 | Phase 1 Clinical | Forma Therapeutics Holdings Inc | Colorectal Neoplasms; Solid tumours | Details |
| Targeted KRAS TCR-T cell therapy(Immuxell Biotech) | Clinical | Shanghai Immuxell Biotech Ltd | Carcinoma, Pancreatic Ductal | Details | |
| CWG-59r | CWG-59r; CWG-59-r; CWG59r | Clinical | Cellworks Group | Neoplasms | Details |
| CWG-71b | CWG-71b; CWG-71-b; CWG71b | Clinical | Cellworks Group | Neoplasms | Details |
| CWG-89 | CWG-89 | Clinical | Cellworks Group | Neoplasms | Details |
| CWG-71a (Cellworks Group) | CWG-71a | Clinical | Cellworks Group Inc | Neoplasms | Details |